Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin sales by physicians

This article was originally published in The Tan Sheet

Executive Summary

Sale of vitamins in physicians' offices is "ethically suspect," according to American College of Physicians-American Society of Internal Medicine guidelines published in the Annals of Internal Medicine Dec 7. The position paper, "Selling Products Out of the Office," maintains "vitamin supplements...are neither emergent treatments nor unlikely to be available elsewhere." The sale of such products in doctors' offices also "may affect the trust necessary to sustain the patient-physician relationship," the paper states, thus physicians should fully disclose any financial interest in selling the products and offer alternatives. In June, the American Medical Association House of Delegates adopted voluntary guidelines discouraging physician in-office sales of health-related products (1"The Tan Sheet" July 5, p. 7)

You may also be interested in...



AMA Discourages Physician Sale Of "Health-Related Products"

American Medical Association voluntary guidelines adopted at the group's annual meeting in Chicago June 20-24 discourage physician in-office sale of "health-related products." The practice "presents a financial conflict of interest, risks placing undue pressure on the patient, and threatens to erode patient trust and the primary obligation of physicians to serve the interests of their patients before their own," an AMA report states.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel